Testing a higher dose lung cancer medication given every other day

This trial is testing furmonertinib, a targeted lung cancer medication, to see if giving it at a higher dose every other day is more effective and safer than the standard daily dose. The study focuses on patients with a specific type of lung cancer (with EGFR mutations) whose cancer has spread to the lining around the brain and spinal cord — a serious condition that is difficult to treat. Researchers want to understand whether the higher alternate-day dosing helps the medication reach better levels in the fluid around the brain, where it's needed most.

Cancer that spreads to the membrane around the brain and spinal cord is a severe complication that current treatments struggle to control well. This medication may work better at higher doses, and taking it every other day instead of daily might allow it to penetrate the brain better while still being safe.